Feasibility, safety, and short-term efficacy of ultrasound-guided radiofrequency ablation for abdominal wall endometriosis: preliminary results from a single center

Nhan Hien Phan, Le NT, Ngoc Trung Le, Nguyen TK, Thanh Khiem Nguyen, Thai Binh Nguyen, Nguyen TB
Abdominal radiology (New York) · 2026 · doi:10.1007/s00261-026-05766-w · PMID:42667387 · W7204649298
article OA: closed public-domain-us
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-01 ⓘ

This single-center study evaluated ultrasound-guided radiofrequency ablation for abdominal wall endometriosis in nineteen patients, demonstrating the procedure's feasibility and safety with significant short-term reductions in pain severity and lesion size at three months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE: To evaluate the feasibility, safety, and short-term outcomes of ultrasound-guided radiofrequency ablation (RFA) for abdominal wall endometriosis (AWE). MATERIALS AND METHODS: This retrospective single-center study included 19 patients with AWE (mean age, 35.5 ± 5.0 years) with 29 lesions who underwent ultrasound-guided RFA between December 2023 and January 2026. AWE was diagnosed based on clinical symptoms and imaging findings on ultrasonography and magnetic resonance imaging; biopsy was performed in atypical cases. RFA was performed using an 18-gauge electrode with the moving-shot technique under local anesthesia combined with intravenous analgesia. Complications were classified according to the SIR classification. Short-term technical efficacy was assessed at 3 months based on clinical symptoms and changes in lesion size on imaging. RESULTS: All patients presented with abdominal pain, including 14 patients (73.7%) with cyclic pain. The mean preprocedural VAS score was 7.37 ± 1.42. A palpable mass was present in 17 patients (89.5%), and two patients (10.5%) had a history of prior surgery for AWE. The mean maximum lesion diameter decreased from 25.1 ± 17.47 mm before treatment to 13.4 ± 10.6 mm at 3 months (p < 0.01). The mean lesion volume decreased from 5.65 ± 7.41 mL to 1.27 ± 1.37 mL (p < 0.01). The mean VAS score decreased to 1.72 ± 2.78 at 3 months (p < 0.01). Three mild adverse events (15.8%) were observed. CONCLUSION: Ultrasound-guided RFA is a feasible and safe treatment option for AWE, providing short-term reductions in pain severity and lesion size.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (22)

Source provenance

europepmc
last seen: 2026-09-07T06:12:11.729357+00:00
openalex
last seen: 2026-09-07T06:04:16.255793+00:00
pubmed
last seen: 2026-09-07T06:05:54.391840+00:00
unpaywall
last seen: 2026-09-07T06:27:18.705824+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine